Several key developments have taken place in the biotech and pharmaceutical industry involving Sanofi (ENXTPA:SAN). The company has reportedly entered into a $2.56 billion autoimmune deal with Earendil Labs. However, the US FDA has raised concerns about the potential risk of severe liver injury, leading to the rejection of Sanofi's MS drug tolebrutinib. Despite these setbacks, the company is moving forward with a $2.2 billion deal with vaccine manufacturer Dynavax.
Furthermore, Sanofi has announced a $30 million investment to beef up Enable Injections’ manufacturing capabilities. Recent moves with the FDA include an agreed review of the age range for a diabetes drug, and a priority review for another diabetes drug, Tzield. On an international level, Sanofi launched plozasiran in China following approval by the NMPA, and SK bioscience released its meningococcal vaccine MenQuadfi in Korea.
Sanofi has also faced troubles with its tolebrutinib, experiencing FDA delays and trial misses. Nevertheless, the company is advancing with a new Phase 3 study of Frexalimab in MS. Lastly, Sanofi is planning to offer insulin products at $35 per month for all US patients while consistently working with artificial intelligence to improve drug discovery and production.
Sanofi News Analytics from Thu, 03 Apr 2025 20:10:10 GMT to Sat, 10 Jan 2026 11:45:33 GMT - Rating -3 - Innovation 6 - Information 8 - Rumor -4
